In an interview to ET, Pranav Amin, Managing Director of Alembic Pharmaceuticals said the management still remains bullish on the US market...

The company had posted a net profit of Rs 333.37 crore for the corresponding period of the previous fiscal, Alembic Pharmaceuticals said in...

Earlier this month, the US drug regulator had issued a ‘Form 483’ to the facility of the drug company with five observations.

As per the USFDA, a Form 483 is issued to a firm's management at the conclusion of an inspection when an investigator has observed any cond...

USFDA issued a form 483 with two observations, the drug firm said in a filing to BSE.

Cadila Healthcare is an example of how a supposedly severe FDA clamp could also translate into an opportunity to accumulate the stock.

Stock may see a sell-off on earnings downgrades & FDA warning, but co has not revised revenue guidance & FIs have steadily raised holdings.

In many cases, these companies have been barred from selling their drugs in the US and other countries, although Indian firms account for a...

The US is the largest market for domestic generic companies, contributing 25-55% of revenues for large companies, while India supplies arou...

The inspectors chided the firm for not documenting alarm events that occur during the routine tablet compression, among other observations.

This is the third such recall for Sun which agreed to buy troubled fellow drug maker Ranbaxy in March this year to create the world's fifth...

Analysts expect that the problems of Indian generic manufacturers could only go up as the foreign inspections of FDA will only rise.

Analysts had pointed out that the import alert by the US Food and Drug Administration on the facility was unlikely to cause any significant...

Rejecting US allegations related to intellectual property rights, India said that it is ready to discuss the matter at WTO as it has not br...

Shares of Sun Pharma continued to remain under pressure for second straight session after the USFDA issued an Import Alert to its plant.

Facilities of leading Indian drugmakers including Ranbaxy and Wockhardt were blacklisted by the US regulator last year.

Shares of Sun Pharmaceutical Industries today fell by over 5 per cent after the US Food and Drug Administration banned import of drugs from...